2024-01-10 06:33:38 ET
- Nyxoah ( NASDAQ: NYXH ) has expected Q4 revenue to be ~€1.8M, up 40% from the prior year and 87% sequentially.
- FY23 revenue is expected to be ~€4.3M, up 41% Y/Y.
- Ended the year with 48 active German accounts.
- “We are excited with the strong preliminary fourth quarter sales, which are anticipated to be nearly double from last quarter. This anticipated growth reflects both strong underlying demand for Genio and focus on streamlining the patient referral pathway through initiatives such as our direct-to-consumer online campaigns launched in March,” commented Olivier Taelman, Chief Executive Officer. “This performance throughout 2023 sets the stage for an exciting 2024, as in a few months we expect to report data from our DREAM US pivotal trial, file for FDA approval, begin preparations to enter the US market, and begin to see contribution from the ResMed commercial partnership in Germany.”
- NYXH +14.8% premarket to $5.17
- Source: Press Release
For further details see:
Nyxoah expects to almost double revenue in 4Q23